Boston Scientific Stung With Across-The-Board Corporate Warning Letter
This article was originally published in The Gray Sheet
Executive Summary
FDA is targeting Boston Scientific with a rare and far-reaching enforcement measure that could prevent some of the firm's investigational products from receiving market approval in the near term